PATENT CLAIM ANALYSIS

Application Number: 15908504
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-07
Patent Classification: ["514", "418000"]

Abstract:
Some embodiments include methods for treating, preventing, reversing, halting, or slowing the progression of cancer, comprising administering to a subject in need thereof an effective amount of one or more chemotherapeutic agents, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition, wherein at least one of the chemotherapeutic agents is a cytotoxic granulocyte colony-stimulating factor receptor (GCFR) modulator. Methods are also disclosed for treating, preventing, reversing, halting, or slowing the progression of a hematopoietic disorder, comprising administered a therapeutically effective cytotoxic amount of a GCFR modulator to a subject in need thereof.

Claim (Index 23):
The method of  claim 22 , wherein the chemotherapeutic agent is selected from the group consisting of an alkylating agent, anthracycline, cytoskeletal disruptor, epothilone, histone deacetylase inhibitor, topoisomerase inhibitor, kinase inhibitor, monoclonal antibody, nucleotide analog, peptide antibiotic, platinum-based agent, retinoid, and vinca alkaloid.

Metadata:
- Claim Count in Document: 26.0
- Percentile: 88.0
- Lexical Diversity: 1.89655
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14775587', '14357551', '15247164', '14977011', '15648349']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8218782464443422
- 35 USC 102 Novelty (BERT): 0.5484321020517122
- Combined Prediction Score: 0.7945336320050792
- Mean Citation Score: 341.537702
- Max Citation Score: 434.3427400000001
- Similarity Product: 287.8853513782001

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test